Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

Clinical Pharmacology and Therapeutics
Alex SparreboomHoward L McLeod

Abstract

The adenosine triphosphate-binding cassette transporter ABCG2 (breast cancer resistance protein [BCRP]) functions as an efflux transporter for many drugs, including the topoisomerase I inhibitor diflomotecan, and is expressed at high levels in the intestine and liver. We performed an exploratory analysis to evaluate the effects of the natural allelic variant ABCG2 421C>A on the pharmacokinetics of diflomotecan. The drug was administered to 22 adult white patients with cancer as a 20-minute infusion (dose, 0.10-0.27 mg), followed 2 weeks later by an oral solution (dose, 0.10-0.35 mg). The ABCG2 421C>A genotype significantly affected the pharmacokinetics of diflomotecan; in 5 patients heterozygous for this allele, plasma levels after intravenous drug administration were 299% (P =.015) of those in 15 patients with wild-type alleles, at mean values of 138 ng x h/mL x mg(-1) (95% confidence interval, 11.3-264 ng x h/mL x mg(-1)) versus 46.1 ng x h/mL x mg(-1) (95% confidence interval, 25.6-66.7 ng x h/mL x mg(-1)), respectively. Diflomotecan levels were not significantly influenced by 11 known variants in the ABCB1, ABCC2, cytochrome P450 (CYP) 3A4, and CYP3A5 genes. These findings provide the first evidence linking variant ABCG2 al...Continue Reading

Citations

Oct 30, 2008·Pharmaceutical Research·Tomoka FurukawaToshihisa Ishikawa
Jul 2, 2009·Pharmaceutical Research·Sarah Shugarts, Leslie Z Benet
Jan 30, 2010·Molecular Pharmaceutics·Vincent J Venditto, Eric E Simanek
Nov 26, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Wei YueKim L R Brouwer
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·P Krishnamurthy, J D Schuetz
Sep 9, 2005·The AAPS Journal·Qingcheng Mao, Jashvant D Unadkat
Feb 16, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kazuya Maeda
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Jing Li, Martin H Bluth
Aug 7, 2008·Pharmacogenomics·George Cusatis, Alex Sparreboom
May 28, 2010·Pharmacogenomics·Ekaitz Errasti-Murugarren, Marçal Pastor-Anglada
Jul 6, 2014·Expert Opinion on Drug Metabolism & Toxicology·Mark J Canet, Nathan J Cherrington
Mar 28, 2008·Expert Opinion on Drug Metabolism & Toxicology·Ying HuangJeffrey Wang
Mar 29, 2008·Expert Opinion on Drug Metabolism & Toxicology·Orsolya PolgarSusan E Bates
May 9, 2008·Drug Metabolism Reviews·Ulrike Gradhand, Richard B Kim
Dec 5, 2008·Expert Opinion on Investigational Drugs·Judith R Kroep, Hans Gelderblom
Jan 21, 2011·Expert Opinion on Drug Metabolism & Toxicology·Erika K Pollex, Janine R Hutson
Aug 28, 2014·Expert Opinion on Drug Metabolism & Toxicology·Oliver Bruhn, Ingolf Cascorbi
Jan 8, 2013·Expert Opinion on Drug Metabolism & Toxicology·Rebecca Schnepf, Oliver Zolk
Sep 30, 2010·Expert Opinion on Drug Metabolism & Toxicology·Maren PoguntkeOliver Zolk
Dec 29, 2010·Advances in Pharmacological Sciences·Toshihisa IshikawaToshihiko Kuroiwa
Feb 7, 2016·The Journal of Pharmacology and Experimental Therapeutics·Kristin M BircsakLauren M Aleksunes
May 19, 2007·British Journal of Clinical Pharmacology·Ho-Sook KimJae-Gook Shin
Oct 5, 2011·Essays in Biochemistry·Akina TamakiSusan E Bates
Nov 2, 2005·Expert Opinion on Pharmacotherapy·Aki SakuraiToshihisa Ishikawa
Dec 1, 2005·Expert Opinion on Pharmacotherapy·Sharon Marsh
May 29, 2009·Clinical Pharmacology and Therapeutics·J E KeskitaloM Niemi
Oct 2, 2007·Current Problems in Cancer·Russell P Kruzelock, William Short
May 17, 2006·Drug Metabolism and Pharmacokinetics·Keiko MaekawaJun-ichi Sawada

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C M F KruijtzerJ H Schellens
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Floris A de JongHoward L McLeod
Ginekologia polska
Adam MaciejczykPaweł Surowiak
Clinica Chimica Acta; International Journal of Clinical Chemistry
Wei ZhangHong-Hao Zhou
© 2022 Meta ULC. All rights reserved